科伦药业：子公司芦康沙妥珠单抗获国家药监局批准第三项适应症

Core Viewpoint - The company announced that its subsidiary, Sichuan Kelun-Botai Biopharmaceutical Co., Ltd., received approval for a third indication of its antibody-drug conjugate, sac-TMT (also known as SKB264/MK-2870), for treating adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment [1] Company Summary - The approved drug, sac-TMT, targets TROP2 and is positioned to address a significant patient population in the NSCLC segment [1] - This approval marks a significant milestone for the company, expanding its product offerings in the oncology space [1] Industry Summary - The approval of sac-TMT aligns with the growing trend of developing targeted therapies for cancer treatment, particularly in the NSCLC market [1] - The NSCLC market is increasingly competitive, with a focus on innovative therapies that can provide options for patients who have limited treatment responses [1]